HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication

For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is a regimen that can include up to 40 pills a day. With a $250 million investment from Blackstone Life Sciences, Anagram Therapeutics hopes to reduce that pill burden to just three pills daily

By FierceBiotech · May 10, 2026 · via FierceBiotech
Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
dealsformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Lilly, Gilead lead pharma’s M&A boom
DealsBioPharma Dive ↗
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer a…
May 8, 2026
Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
DealsFiercePharma ↗
Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalys…
May 8, 2026
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
DealsFierceBiotech ↗
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
Roche is set to pay out a little more than $1 billion to acquire digital pathology specialist Path AI in a mov…
May 8, 2026